TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03163511

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-02 Combination Product
Description: PEC-01 cells loaded into a Delivery Device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-02 Combination Product
Description: PEC-01 cells loaded into a Delivery Device
Study: NCT04516044

Intervention type: BEHAVIORAL
Intervention: Video games
Description: See arm description
Study: NCT00337350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Rosiglitazone 4mg, one capsule per day for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo for rosiglitazone 4mg/day
Study: NCT02852772

Intervention type: BEHAVIORAL
Intervention: Cognitive function tests

Intervention type: BEHAVIORAL
Intervention: Cognitive function tests
Study: NCT01967758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
Study: NCT03360981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Incretins
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
Study: NCT01967758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 3
Description: Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
Study: NCT04139902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab (TSR-042) and TSR-022 (combination)
Description: If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks.
Study: NCT03885206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level of healthcare services
Description: Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
Study: NCT01967758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
Study: NCT02177578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
Study: NCT06120361

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma APS 2 score
Description: APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study: NCT02177578

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Subventricular Zone radiation
Description: Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neural Progenitor Cell Sparing radiation
Description: Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions
Study: NCT05274139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-MTX-Ara-C regimen
Description: HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTD regimen
Description: FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
Study: NCT06120361

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma p-tau217/np-tau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma p-tau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light (NfL)
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI and CT of the brain
Description: Structural brain imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Different cognitive tests
Description: Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
Study: NCT02354170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03911544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS monitor
Description: Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
Study: NCT00649415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piroxicam
Description: piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
Study: NCT01866722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduction
Description: Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5Rs
Description: Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
Study: NCT03015883

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT04232670

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EUS + SHAM
Description: Endoscopic Ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS + Pancreatic Endotherapy
Description: Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
Study: NCT01321073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model 10642 Implantable Intravascular Catheter
Description: This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
Study: NCT01551537

Intervention type: OTHER
Intervention: Cervarix data collection
Description: Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.

Intervention type: OTHER
Intervention: Data Collection
Description: All adverse events will be recorded by diary card, follow-up visit or telephone contact.
Study: NCT03087162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg once daily
Description: Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 mg once daily
Description: Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
Study: NCT04392570

Intervention type: DIAGNOSTIC_TEST
Intervention: Fasting
Description: blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
Study: NCT04409769

Intervention type: OTHER
Intervention: Description of use of ceftaroline and ceftobiprole
Description: Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
Study: NCT03937869

Intervention type: DRUG
Group type: OTHER
Intervention: Secnidazole
Description: One dose
Study: NCT05994560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With temporary occlusion
Description: at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed

Intervention type: OTHER
Group type: OTHER
Intervention: With temporary occlusion
Description: at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
Study: NCT04586361

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RegenLab PRP
Description: PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
Study: NCT00517803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yogurt B: with various micronutrients
Description: 175g probiotic yogurt / day 25% RDA for each nutrient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Yogurt A: Kaiser micronutrients
Description: 175g probiotic yogurt/ day 25% RDA for each nutrient
Study: NCT03909139

Intervention type: BIOLOGICAL
Intervention: BMAC
Description: A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone marrow is aspirated then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers) is removed. The buffy coat layer contains mesenchymal stromal cells. This is called BMAC or Bone Marrow Aspirate Concentrate. The BMAC will be injected into the intra-articular space.
Study: NCT00517803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt C: with basic micronutrients
Description: 175g yogurt/ day 25% RDA for each nutrient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Yogurt D: Placebo -- no added micronutrients
Description: 175g/day probiotic yogurt
Study: NCT01586208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproic acid (VPA)
Description: Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproic acid (VPA)
Description: Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
Study: NCT03673514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
Study: NCT00834158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: 1 time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: 1 time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVE
Description: 1 time
Study: NCT02092701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT03355092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vBloc Therapy
Description: The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
Study: NCT01992939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized pulse oximetry probe with external heat pack
Description: Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized pulse oximetry probe with external heat pack
Description: Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pulse Oximetry Probe
Description: Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
Study: NCT01292837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
Study: NCT03259113

Intervention type: DEVICE
Group type: OTHER
Intervention: Insertable cardiac monitor
Description: Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
Study: NCT01992939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pulse Oximetry Probe
Description: Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
Study: NCT02922491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: daily intake of vitamin E
Study: NCT03696186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminal type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luminal type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuroendocrine type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuroendocrine type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atypical type-1
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atypical type-2
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
Study: NCT06184087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational/Instructional
Description: ICAP constructive-interactive engagement mode

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational/Instructional
Description: ICAP constructive-interactive engagement mode
Study: NCT03777215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active beneficial hormone of the renin-angiotensin system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be used as the placebo comparator.
Study: NCT02922491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: daily intake of vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: daily intake of starch (control)
Study: NCT03437668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSE
Description: WSE tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet
Study: NCT04087096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered at postoperative months 1, 7, and 13
Study: NCT00295503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV every 3 weeks
Study: NCT04087096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at postoperative months 1, 7, and 13
Study: NCT02957565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaires
Description: Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaires
Description: Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
Study: NCT04087096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Study: NCT02957565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaires
Description: Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
Study: NCT03356483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (0.25mg/kg)
Description: Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
Study: NCT00295503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2 every 3 weeks
Study: NCT03356483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin (250mg)
Description: A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.